LEMAITRE VASCULAR INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $LMAT in the last 7 days.
No SEC Form 4 filings for $LMAT in the last 30 days.
See all $LMAT insider activity →LeMaitre Vascular announced that David B. Roberts will retire as President on December 31, 2026, but will remain on the company's Board of Directors. Roberts has served as an executive for 29 years and was reelected as a director in 2026 for a term ending in 2029. The company has not disclosed a replacement.
LEMAITRE VASCULAR INC (LMAT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On October 9, 2026, David B. Roberts notified LeMaitre Vascular, Inc. (the “Company”) of his intent to retire as an emp
LeMaitre Vascular (Nasdaq:LMAT) will release Q3 2026 financial results on Nov. 4 after market close, followed by a conference call at 5:00 PM EST to discuss results, business highlights, and company outlook. The call is accessible via registration and will also be available as an audio webcast.
Recent LMAT coverage spans earnings, corporate actions and sector analysis.
Executive retirement may cause modest stock pressure as investors assess leadership transition.
Board-level continuity is maintained, but the President succession risk may prompt investors to reassess near-term leadership execution.
Near-term trading focus shifts to the Nov. 4 earnings event and the associated call, with positioning likely ahead of the print.
No fresh news; market has priced the miss and guidance downgrade.
Higher short interest may depress the stock.
AlphAI scores every news story that mentions LMAT with an AI model for sentiment and relevance, and aggregates insider trades from LEMAITRE VASCULAR INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
LeMaitre Vascular announced that David B. Roberts will retire as President on December 31, 2026, but will remain on the company's Board of Directors. Roberts has served as an executive for 29 years and was reelected as a director in 2026 for a term ending in 2029. The company has not disclosed a replacement.
1 min readLEMAITRE VASCULAR INC (LMAT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On October 9, 2026, David B. Roberts notified LeMaitre Vascular, Inc. (the “Company”) of his intent to retire as an emp
3 min readLeMaitre Vascular (Nasdaq:LMAT) will release Q3 2026 financial results on Nov. 4 after market close, followed by a conference call at 5:00 PM EST to discuss results, business highlights, and company outlook. The call is accessible via registration and will also be available as an audio webcast.
2 min readBaxter (BAX) reported Q2 revenue of $2.96B, up 5.3% YoY, beating estimates. LeMaitre (LMAT) reported $70.38M, up 9.6% YoY, missing estimates. STERIS (STE) reported $1.49B, up 7.3% YoY, in line with estimates. Lantheus (LNTH) reported $388.2M, up 2.7% YoY, beating estimates. Stocks are down since reporting.
2 min readHedge funds reduced long positions in Amazon, Tesla, Meta, Alphabet, and Apple in August, while increasing shorts in Amazon, Alphabet, and Apple. AI debt financing raised concerns about future cash flows. Nvidia saw a decline in short interest. MACOM Technology Solutions shifted from short to long bias. Semiconductor sector sentiment turned modestly less bullish, with Applied Materials, Nvidia, and Lam Research seeing the most long crowding.
3 min readIntegra LifeSciences (IART) reported flat Q2 revenue of $418.8M, meeting expectations. Teleflex (TFX) saw 28.9% revenue growth, beating estimates. LeMaitre (LMAT) missed expectations with 9.6% growth. Intuitive Surgical (ISRG) reported 18.5% growth, beating estimates. All stocks declined post-earnings, with IART down 17.7%, TFX flat, LMAT down 24.9%, and ISRG down 12.3%.
3 min readA specialty-stocks earnings recap compares Q2 results for LeMaitre (LMAT), Teleflex (TFX), Integra LifeSciences (IART), and Intuitive Surgical (ISRG). The group’s revenues beat consensus by 0.8%, but next-quarter guidance was 1.6% below. LMAT revenue was $70.38M (+9.6%) but missed by 1.7% and EPS. TFX revenue was $570.3M (+28.9%) beat by 2%. IART revenue $418.8M flat, in line. ISRG revenue $2.89B (+18.5%) beat by 2.6%.
7 min readLeMaitre Vascular (LMAT) reported Q2 2026 revenue of $70.4 million, up 10% organically, with diluted EPS of $0.74 (+23%). Gross margin rose to 72.1%. Artegraft sales grew 34% and now 21% of sales, while catheter sales fell 11%. Full-year guidance: revenue $274.3M-$278.3M, EPS $2.84-$2.94.
6 min readSimply Wall St reports LeMaitre Vascular (LMAT) released Q2 2026 results with higher sales and net income, updated guidance, and a reaffirmed cash dividend. It notes the stock’s recent 7-day and 30-day returns of about 21% and 21% versus 3- and 5-year TSR near 48% and 52%. It cites a fair value of $118.75 versus a last close of $81.45 and a P/E of 28.4x.
6 min readConestoga Capital Advisors’ Q2 2026 investor letter discussed LeMaitre Vascular (NASDAQ:LMAT), citing 10% organic revenue growth, 72.1% gross margins, and adjusted EPS of $0.68 versus $0.66 consensus. Despite strong fundamentals, LMAT shares fell after earnings as investors took profits. LMAT closed Aug. 5 at $79, with a $1.81B market cap.
4 min read
